Nextech V Oncology S.C.S. SICAV-SIF 13D and 13G filings for Kinnate Biopharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:16 pm Sale | 2023-12-31 | 13G | Kinnate Biopharma Inc. KNTE | Nextech V Oncology S.C.S. SICAV-SIF | 0 0.000% | -2,329,480 (Position Closed) | Filing |
| 2023-02-14 4:32 pm Sale | 2022-12-31 | 13G | Kinnate Biopharma Inc. KNTE | Nextech V Oncology S.C.S. SICAV-SIF | 2,329,480 5.300% | -678,763 (-22.56%) | Filing |
| 2021-02-16 4:00 pm Purchase | 2020-12-31 | 13G | Kinnate Biopharma Inc. KNTE | Nextech V Oncology S.C.S. SICAV-SIF | 3,008,243 6.900% | 3,008,243 (New Position) | Filing |